Experts optimistic about Pfizer's crizotinib to treat subset of lung cancer
This article was originally published in Scrip
Executive Summary
Pfizer's oral ALK and cMET inhibitor crizotinib (PF-02341066) has resulted in high response rates in an early clinical trial in a small subset of non-small-cell lung cancer (NSCLC) patients with EML4-ALK fusion oncogenes, giving further support to the concept of "personalised medicine" in cancer treatment.